First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA

Sandeep Anand Padala; Anusha Vakiti; John Jason White; Laura Mulloy; Azeem Abdul Mohammed

doi:10.14740/jocmr4228

First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA

Sandeep Anand Padala, Anusha Vakiti, John Jason White, Laura Mulloy, Azeem Abdul Mohammed

Nephrology

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Critically ill patients with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) develop respiratory failure and septic shock. Extracorporeal blood purification is proposed as an adjuvant therapy for sepsis and aims at controlling the dysregulated autoimmune system. We describe our experience in treating COVID-19 patients with the oXiris® hemofilter which adsorbs both cytokines and endotoxins, provides renal replacement therapy and has anti-thrombogenic properties. It was approved by the US Food and Drug Administration (FDA) under emergency use authorization for COVID-19 patients in April 2020.

Original language	English (US)
Pages (from-to)	454-457
Number of pages	4
Journal	Journal of Clinical Medicine Research
Volume	12
Issue number	7
DOIs	https://doi.org/10.14740/jocmr4228
State	Published - 2020

Keywords

Acute kidney injury
Adsorptive hemofilter
Coronavirus 2
COVID-19
oXiris
SARS-CoV-2

ASJC Scopus subject areas

General Medicine

Access to Document

10.14740/jocmr4228

Cite this

@article{a91d9650a13b4b86bc5acbd9349cbe3d,

title = "First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA",

abstract = "Critically ill patients with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) develop respiratory failure and septic shock. Extracorporeal blood purification is proposed as an adjuvant therapy for sepsis and aims at controlling the dysregulated autoimmune system. We describe our experience in treating COVID-19 patients with the oXiris{\textregistered} hemofilter which adsorbs both cytokines and endotoxins, provides renal replacement therapy and has anti-thrombogenic properties. It was approved by the US Food and Drug Administration (FDA) under emergency use authorization for COVID-19 patients in April 2020.",

keywords = "Acute kidney injury, Adsorptive hemofilter, Coronavirus 2, COVID-19, oXiris, SARS-CoV-2",

author = "Padala, {Sandeep Anand} and Anusha Vakiti and White, {John Jason} and Laura Mulloy and Mohammed, {Azeem Abdul}",

note = "Publisher Copyright: {\textcopyright} The authors | Journal compilation",

year = "2020",

doi = "10.14740/jocmr4228",

language = "English (US)",

volume = "12",

pages = "454--457",

journal = "Journal of Clinical Medicine Research",

issn = "1918-3003",

publisher = "Elmer Press Inc",

number = "7",

}

TY - JOUR

T1 - First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA

AU - Padala, Sandeep Anand

AU - Vakiti, Anusha

AU - White, John Jason

AU - Mulloy, Laura

AU - Mohammed, Azeem Abdul

N1 - Publisher Copyright: © The authors | Journal compilation

PY - 2020

Y1 - 2020

N2 - Critically ill patients with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) develop respiratory failure and septic shock. Extracorporeal blood purification is proposed as an adjuvant therapy for sepsis and aims at controlling the dysregulated autoimmune system. We describe our experience in treating COVID-19 patients with the oXiris® hemofilter which adsorbs both cytokines and endotoxins, provides renal replacement therapy and has anti-thrombogenic properties. It was approved by the US Food and Drug Administration (FDA) under emergency use authorization for COVID-19 patients in April 2020.

AB - Critically ill patients with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) develop respiratory failure and septic shock. Extracorporeal blood purification is proposed as an adjuvant therapy for sepsis and aims at controlling the dysregulated autoimmune system. We describe our experience in treating COVID-19 patients with the oXiris® hemofilter which adsorbs both cytokines and endotoxins, provides renal replacement therapy and has anti-thrombogenic properties. It was approved by the US Food and Drug Administration (FDA) under emergency use authorization for COVID-19 patients in April 2020.

KW - Acute kidney injury

KW - Adsorptive hemofilter

KW - Coronavirus 2

KW - COVID-19

KW - oXiris

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85096595363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096595363&partnerID=8YFLogxK

U2 - 10.14740/jocmr4228

DO - 10.14740/jocmr4228

M3 - Article

AN - SCOPUS:85096595363

SN - 1918-3003

VL - 12

SP - 454

EP - 457

JO - Journal of Clinical Medicine Research

JF - Journal of Clinical Medicine Research

IS - 7

ER -

First Reported Use of Highly Adsorptive Hemofilter in Critically Ill COVID-19 Patients in the USA

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this